United States - English - NLM (National Library of Medicine)

bavarian nordic a/s - vaccinia virus modified strain ankara-bavarian nordic non-replicating antigen (unii: tu8j357395) (vaccinia virus modified strain ankara-bavarian nordic non-replicating antigen - unii:tu8j357395) - jynneos is a vaccine indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available human data on jynneos administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. the effect of jynneos on embryo-fetal and post-natal development was evaluated in four developmental toxicity studies conducted in female rats and rabbits. in two studies, rats were administered a single human dose of jynneos (0.5 ml) once prior to mating and on one or two occasions during gestation. in the third study, rats were administered a single human dose of jynneos (0.5 ml) on two occasions during gestation. in the fourth study, rabbits were ad

Canada - English - Health Canada

bavarian nordic as - salmonella typhi ty21a live attenuated - capsule (enteric-coated) - 10000000000cfu - salmonella typhi ty21a live attenuated 10000000000cfu - vaccines

Canada - English - Health Canada

bavarian nordic as - modified vaccinia virus (ankara-bavarian nordic) - suspension - 50000000ccid50 - modified vaccinia virus (ankara-bavarian nordic) 50000000ccid50 - vaccines

European Union - English - EMA (European Medicines Agency)

bavarian nordic a/s - modified vaccinia ankara - bavarian nordic (mva-bn) virus - smallpox vaccine; monkeypox virus - other viral vaccines, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorrhagic fever, ebola - vaccines - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.,

European Union - English - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, strain cvd 103-hgr, live - cholera - vaccines - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older.this vaccine should be used in accordance with official recommendations.

Philippines - English - FDA (Food And Drug Administration)

rej diamond pharmaceuticals, inc. - cassi angustifolia vahl (senna leaves) - herbal tea - 2 g

New Zealand - English - Medsafe (Medicines Safety Authority)

biocelect new zealand ltd - salmonella typhi strain ty21a berna 2000 million organisms (minimum); salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum); salmonella typhi strain ty21a berna 2000 million organisms - modified release capsule - 2000 million organisms - active: salmonella typhi strain ty21a berna 2000 million organisms (minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate lactose fast flo iron oxide red iron oxide yellow lactose monohydrate magnesium stearate sucrose titanium dioxide active: salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate sucrose titanium dioxide active: salmonella typhi strain ty21a berna 2000 million organisms excipient: ascorbic acid diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate methanol methylene chloride protein hydrolysate sucrose titanium dioxide - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

Israel - English - Ministry of Health

kamada ltd, israel - viable salmonella typhi ty21a cells - gastro resistant hard capsule - viable salmonella typhi ty21a cells - vivotif is indicated for active oral immunisation against typhoid fever, caused by salmonella enterica serovar typhi, (s. typhi), in adults and children aged five years and older.this vaccine should be used in accordance with official recommendations

Canada - English - Health Canada

bavarian nordic as - vibrio cholerae, strain cvd 103-hgr, live - powder for suspension - 2000000000unit - vibrio cholerae, strain cvd 103-hgr, live 2000000000unit